Medicinal Chemistry – Lead Identification

Facility part of the DDD platform

The Medicinal Chemistry - Lead Identification facility will take on, explore, and optimize molecules in drug discovery projects. Synthetic and computational chemistry will be at the core of the so-called Design-Make-Test-Analyze cycle that characterizes a small molecule drug discovery program. The mission is to deliver small drug-like molecules with potency, selectivity, physicochemical and ADMET properties of sufficient quality to allow proof-of-concept animal studies. We work in close collaboration with our colleges in the hit-to lead facility https://www.scilifelab.se/facilities/hit2lead/.



  • Organic synthesis of bioactive compounds (small molecules and peptides).
  • Medicinal chemistry expertize.
  • Iterative design, synthesis and analysis of assay data to improve compound properties.
  • Compound characterization, structure determination and purity analysis.
  • Quantitative structure based activity relationships.
  • Scale-up synthesis of bioactive compounds.
  • Selection and purchase of commercial compounds.
  • Synthesis of reference compounds.
  • Competitive Intelligence
  • In collaboration with Medicinal chemistry Hit2Lead
    • Computer-based drug design



  • Analytical UHPLC-MS.
  • Automated flash chromatography systems.
  • GCMS instruments.
  • Hardware and software for Computer-Aided Drug Design.
  • Microwave batch reactors.
  • Microwave continuous flow reactors.
  • NMR spectrometers.
  • Peptide synthesizer.
  • Preparative HPLC instruments.


M. Ladds, I. van Leeuwen, C. Drummond, S. Chu, A. Healy, G. Popova A. Fernández, S. Darekar, S. Sedimbi, M. Nekulova, M. Sachweh, J. Cambell, M. Higgins, C. Tuck, M. Popa, M. Safont, P. Gelebart, Z. Fandalyuk, A. Thomson, R. Svensson, A-L. Gustafsson, L. Johansson, K. Färnegårdh, U. Yngve, A. Saleh, M. Haraldsson, A. D'Hollander, M. Franco, Y. Zhao, M. Håkansson, B. Walse, K. Larsson, E. Peat, V. Pelechano, J. Lunec, B. Vojtesek, M. Carmena, W. Earnshaw, A. McCarthy, N. Westwood, M. Arsenian-Henriksson, D. Lane, R. Bhatia, E. McCormack, S. Laín: A DHODH inhibitor increase p53 synthesis and enhances tumor cell killing by p53 degradation blockage. Nature Communications 9 (2018) 1107. DOI: 10.1038/s41467-018-03441-3

J. Wannberg, R. Isaksson, U. Bremberg, M. Backlund, J. Sävmarker, M. Hallberg, M. Larhed: A convenient transesterfication method for synthesis of AT2 receptor ligands with improved stability in human liver microsomes. Bioorg. Med. Chem. Lett. 28 (2018) 519-522. DOI 10.1016/j.bmcl.2017.11.042

R. Isaksson, I. Kumpiņa, J. Sävmarker, M. Larhed, J. Wannberg*: Rapid and straightforward transesterification of sulfonyl carbamates. Tetrahedron Lett 57 (2016) 1476-1478. .DOI 10.1016/j.tetlet.2016.02.071

I. Kumpiņa, R. Isaksson, J. Sävmarker, J. Wannberg, M. Larhed*: Microwave Promoted Transcarbamylation Reaction of Sulfonylcarbamates under Continuous-Flow Conditions. Org. Process Res. Dev.20 (2016) 440-445.DOI 10.1021/acs.oprd.5b00323

P. Wakchaure, U. Bremberg, J. Wannberg, M. Larhed*: Synthesis of enantiopure angiotensin II type 2 receptor [AT2R] antagonist EMA401. Tetrahedron 71 (2015), 6881-6887. DOI: 10.1016/j.tet.2015.07.08